Immunobiome Participates in the 10th Smart Start Excellent Bio Companies Investment Presentation... Conducts IR

[Asia Economy Reporter Hyunseok Yoo] Immunobiome, a microbiome-based new drug research and development company, announced on the 18th that it participated in the ‘10th Smart Start (Excellent Bio Company Investment Presentation)’.

Hosted by the Korea Bio Association and the New Industry Investment Zone Council, the event was held on the 15th at Oakwood Premier COEX Center in Gangnam-gu, Seoul. The event aimed to share investment trends and information related to initial public offerings (IPO) in the bio sector, and to provide IR opportunities targeting bio-specialized investment reviewers for promising domestic bio companies, supporting continuous and stable corporate growth.

Including Immunobiome, five companies were finally selected as IR companies and conducted IR presentations.

Shinhyuk Lim, CEO of Immunobiome, said, “Microbiome-based therapeutics have not yet been commercialized, but it is a blue ocean market expected to grow to a scale of 130 trillion KRW in 2023. Immunobiome aims to develop next-generation disease-customized microbiome-targeted therapeutics based on numerous domestic and international patents on immune regulatory candidate strains and active substances, as well as verified candidate strain selection and efficacy substance derivation technologies.”

He continued, “The anticancer drug IMB001 demonstrated excellent effects when co-administered with existing immune checkpoint inhibitors through animal experiments. We completed preclinical trials in September this year and finished CDMO (Contract Development and Manufacturing Organization) mass production in October. We plan to initiate 1b/2a simultaneous clinical trials for IMB001 in Korea and the United States in the first quarter of next year,” he explained.

Additionally, he stated, “The autoimmune disease therapeutic IMB002 is also scheduled to complete preclinical trials in the first half of next year. The IMB002 strain and strain-derived active substances with hypersensitive immune suppression functions have been validated through research results published in top academic journals such as Science Immunology and Nature Communications.”

Immunobiome has discovered strains that induce immune enhancement or hypersensitive immune suppression, identified the active substances and efficacy derived from these microorganisms, and holds numerous domestic and international patents. The company independently developed the core technology ‘AvatiomeTM’ system, which can analyze from new drug candidate substance derivation to human applicability.

Avatiome is an avatar model system that simulates human immunity and microbiome. Based on the Avatiome system, Immunobiome derives therapeutic microorganisms for immune diseases and various therapeutic candidates, currently establishing pipelines for anticancer drugs, inflammatory bowel disease, and lupus therapeutics. The company plans to continue deriving subsequent pipelines using this system in the future.

This content was produced with the assistance of AI translation services.